Divalproex Sodium
Product Images NDC 50090-3616

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 50090-3616). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1 (Divalproex Fig1)

Figure 1 (Divalproex Fig1)
A bar chart comparing percentages from two studies, Study 1 (YMRS) and Study 2 (MRS), showing the effect of divalproex sodium delayed-release tablets (DVPX) versus placebo (PBO). DVPX bars indicate approximately 60% and 58%, whereas placebo bars indicate 26% and 29%, respectively.*
FDA Label Image

Figure 2 (Divalproex Fig2)

Figure 2 (Divalproex Fig2)
A cumulative percentage responder curve comparing the percent reduction in Clinical Pain Scale (CPS) rate for patients using Divalproex Sodium delayed-release tablets versus placebo. The graph shows percentage of patients on the x-axis and percentage reduction in CPS rate on the y-axis, indicating clinical improvement or worsening.*
FDA Label Image

Figure 3 (Divalproex Fig3)

Figure 3 (Divalproex Fig3)
A line graph labeled as Figure 3 showing the percentage reduction in CRS Rate on the y-axis versus the percentage of patients on the x-axis for High Dose and Low Dose groups. The graph indicates patient improvement and worsening with high and low doses through two curves, solid for High Dose and dashed for Low Dose.*
FDA Label Image

Figure 4 (Divalproex Fig4)

Figure 4 (Divalproex Fig4)
Bar chart titled 'Mean 4-week Migraine Rates' comparing migraine rates for Placebo and Divalproex Sodium Delayed-Release Tablets in two studies. Study 1 and Study 2 each display lower migraine rates for Divalproex Sodium compared to Placebo, with accompanying footnotes on dosages for the delayed-release tablets.*
FDA Label Image

Chemical Structure (Divalproex Str)

Chemical Structure (Divalproex Str)
Chemical structure of Divalproex Sodium showing its molecular components, including carbon chains, carboxylate groups, and sodium ions, represented in a polymeric chain format.*
FDA Label Image

Label Image (Lbl500903616)

Label Image (Lbl500903616)
Divalproex Sodium 250 mg label from A-S Medication Solutions. This label shows the product name, strength, dosage form as delayed-release tablets, quantity of 30 tablets, and storage instructions to keep at 68-77 degrees Fahrenheit. It also includes a lot number, NDC number 50090-3616-0, barcodes, and handling instructions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.